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  To construct a sensory neuropathy model, excess pyrido-
xine (150 mg/kg s.i.d.) was injected subcutaneously in dogs 
over a period of 7 days. During the administrations peri-
od, the dogs experienced body weight reduction and pro-
prioceptive loss involving the hindquarters. After pyridox-
ine administration was completed, electrophysiological re-
cordings showed that the M wave remained at a normal 
state, but the H-reflex of the treated dogs disappeared at 7 
days. The dorsal funiculus of L4 was disrupted irregularly 
in the axons and myelin with vacuolation. The dorsal root 
ganglia of L4, and sciatic and tibial nerves showed degen-
erative changes and vacuolation. However, the lateral and 
ventral funiculi of L4 showed a normal histopathologic 
pattern. Although this subcutaneous administration meth-
od did not cause systemic toxicity and effectively induced 
sensory neuropathy, this study confirmed the possibility of 
producing a pyridoxine-induced sensory neuropathy mod-
el in dogs with short-term administration.
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Introduction 
  Pyridoxine, a form of vitamin B6, is an essential dietary 
constituent [5]. Vitamin B6 occurs in three natural forms: 
pyridoxol (pyridoxine), pyridoxal, and pyridoxamine. 
Pyridoxine is most commonly used as a dietary supplement 
and therapeutic agent. High dose pyridoxine is used in con-
ditions such as premenstrual and carpal tunnel syndromes, 
and has been prescribed as a treatment for ingestion of the 
false morel mushroom, Gyromitra esculenta [4]. The ra-
tionale behind the latter treatment is that the active toxin 
monomethylhydrazine competitively inhibits a pyridox-
ine-dependent step in the synthesis of the neurotransmitter 
gamma-aminobutyric acid [10]. While pyridoxine defi-
ciency causes distal, predominantly sensory neuropathy, 
pyridoxine has also been identified as a neurotoxicant. 
During the 1980s, the medical community was alerted to a 
neurologic disease occurring in individuals consuming 
large quantities of vitamin B6 for prolonged periods of time 
[10]. Investigators described severe sensory neuropathy of 
insidious onset and course associated with chronic abuse of 
oral pyridoxine supplements. The recommended daily oral 
dose is 2-4 mg in human adults. However, with daily oral 
doses of up to 6 g for 12-40 months, one may contract pro-
gressive sensory neuropathy manifested by sensory ataxia, 
diminished distal limb proprioception, paresthesia, and hy-
peresthesia [3,11]. 
  There are many animal model studies based on these data. 
In rat studies, three intraperitoneal dosing regimens are 
generally employed: short term/high dose, 1,200 mg/kg/ 
day for 1-15 days; intermediate dose, 600 mg/kg/day for 
1-15 days; and long term/low dose, 100-300 mg/kg/day for 
up to 12 weeks [13]. Such experimental studies have con-
firmed the morphologic pattern of peripheral nervous sys-
tem lesions in pyridoxine neurotoxicity, reflecting primary 
injury to the cytons of neurons residing in peripheral sen-
sory (dorsal root, trigeminal) ganglia, with secondary de-
generation of axons of affected cells [10]. 
  There have been some experiments wherein sensory neu-
ropathy was induced in dogs with pyridoxine overdose. 
However, these previous experiments used extreme doses 
of pyridoxine or were performed over a long period of time 
[5,8,9]. 
  The incidence of neurodegenerative disorders has been 
increasing in the canine population, and this development 
requires effective countermeasures. However, canine 
models of specific neurodegenerative disorders are pre-
requisite to developing new treatments. The purpose of this 
study was to develop a dog model of sensory neuropathy 
by administering subcutaneous (SC) injections of pyridox-
ine over a short period of time. This differs from other ex-
periments, in which extreme doses of pyridoxine were de-
livered by oral administration or were delivered over a long 
period of time. 
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Materials and Methods
Animals
  Ten dogs (five beagles, three Shih tzus, one Pekingese, 
and one mongrel) were used for determining normal elec-
trophysiological values. There were five male and five fe-
male dogs, all of which were around two years of age. Body 
weight ranged from 4 to 6 kg. 
  Eight dogs (four Shih-tzus, two mongrels, one Pekingese, 
and one Yorkshire terrier) were used for the pyridoxine-in-
duced neuropathy study. There were four male and four fe-
male dogs, all of which were around two years of age. Body 
weight ranged from 4 to 6 kg. Two dogs were in the control 
group, and six dogs were in the experimental group. 
  All dogs were clinically judged to be in good health and to 
be neurologically normal. All experimental dogs had their 
own admission number issued by the Institute of Laborato-
ry Animal Resources, Seoul National University (Korea). 
During the experiment, all dogs were cared for according 
to Animal Care and Use Guidelines from the Institute of 
Laboratory Animal Resources, Seoul National University. 
Body weight and condition were measured every morning 
in the test dogs. 
Pharmacological treatment
  Pyridoxine (Sigma, France) was diluted in a 0.9% sterile 
aqueous solution of sodium chloride and administered to 
each dog SC, once a day, in the morning, for 7 days. The 
pyridoxine solution was prepared immediately before each 
injection. Animals in the control group received a vehicle 
(iso-osmotic sterile aqueous solution of sodium chloride), 
while animals in the experimental group were admini-
stered 150 mg/kg pyridoxine SC, in a concentration of 100 
mg/ml. SC injection was chosen as the route of pyridoxine 
administration because of convenience. The SC dosage 
(150 mg/kg, s.i.d. for 7 days) was decided based on the or-
ally administered dosage of pyridoxine previously shown 
to induce peripheral neuropathy [5]. 
Postural reaction assessments
  Postural reaction (wheelbarrowing, hopping, extensor 
postural thrust, placing, tonic neck reaction, and proprio-
ceptive positioning) assessments were done on all dogs ev-
ery morning during the test period. 
Electrophysiological recordings
  All dogs were pre-anesthetized with atropine (0.1mg/kg 
of body weight, IM). Anesthesia was induced with dia-
zepam and was maintained with isoflurane through a 
semi-closed system. Subcutaneous temperature was main-
tained at 37-38oC. Neuropack2 (Nihon Koden, Japan) was 
used for all recordings. All measurements were performed 
in the left hindlimb of each dog. 
  Direct-evoked muscle potentials (DEMP, M wave) were 
recorded for the tibial nerve using a 1 Hz, 0.5 ms, supra-
maximal stimulus. Stimulating electrodes were positioned 
in the distal tibial nerve. A recording electrode was posi-
tioned in the plantar interosseous muscle. The ground elec-
trode was positioned between the stimulating electrode 
and recording electrode. The recording electrode was a bi-
polar needle electrode. Reflex-evoked muscle potentials 
(REMP, H-reflex) were recorded using a 1 Hz, 0.5 ms, sub-
maximal stimulus. The stimulating electrode was posi-
tioned in the tibial nerve adjacent to the hook, and the re-
cording electrode and ground electrode were positioned in 
the same tibial nerve site where the M wave was measured. 
All measurements were performed at least eight times. 
First, electrophysiological recordings were performed for 
determining normal values. Electrophysiological record-
ings were then performed twice more for the experimental 
group: once before the experiment and once after the test 
period. 
Histopathological analysis
  After the experimental period (10 days from the start of 
the experiment), the dogs were anesthetized with high dose 
tiletamine/zolazepam (Virbac, France) and given propofol 
(Choongwae, Korea) to induce euthanasia. They were then 
perfused transcardially with 0.1 M phosphate-buffered sal-
ine (PBS), followed by 4% paraformaldehyde in 0.1 M 
PBS. After perfusion, the lumbar spinal cord (L4), left and 
right dorsal root ganglia of L4, sciatic nerve, and tibial 
nerve were quickly removed, post-fixed for 4-6 h in the 
same fixative at 4oC, and embedded in paraffin. The tissues 
were sectioned serially to 5 μm thickness with a micro-
tome (Reichert-Jung, Germany), floated onto gelatin- 
coated slides, deparaffinized in xylene, rehydrated in a de-
scending ethanol series, and stained with hematoxylin and 
eosin. The sections were examined under an Olympus 
BX51 microscope (Olympus, Japan) attached to an 
IMT2000 digital camera (iMTechnology, Korea).
Statistical analysis
Paired t-test was done for analysis of body weight and the 
M wave and H-reflex amplitudes before and after pyridox-
ine treatment. Statistical significance was set at p ＜ 0.05.
Results
  Weight measurement showed that there was weight loss 
in the treated group. The weight of control group animals 
was maintained at 5.35 ± 0.21 kg for experimental period. 
The weight of treated group animals decreased from 4.92 ± 
0.40 kg to 4.4 ± 0.43 kg. The difference in body weight be-
fore and after pyridoxine treatment was statistically sig-
nificant (p ＜ 0.05).
  All dogs in the treated group developed neurologic abnor-
malities, characterized especially by ataxia involving first, 
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Fig. 1. On electrophysiological analysis, a control dog showed an
H-reflex (A), but a pyridoxine model dog showed no H-reflex 
(B). Both have normal M waves. The M wave amplitude showed
no remarkable change after pyridoxine treatment, a finding 
which was confirmed in our statistical analysis (p ＜ 0.05). There
was a remarkable change in the H-reflex after treatment in the 
experimental group.
Fig. 2. (A) Normal dorsal funiculus in L4. (B) Dorsal funiculus in
L4 showing disruption and irregularity of axons and myelin with
vacuolation. (C) Normal dorsal root ganglia in L4. (D) Dorsal 
root ganglia in L4 showing chromatolysis with eccentric location
of nucleus (arrow). H&E stain, ×200. 
Fig. 3. (A) Normal sciatic nerve. (B) Sciatic nerve showing 
axonal swelling with vacuolation (arrows). (C) Normal tibial 
nerve. (D) Tibial nerve showing axonal swelling with vacuola-
tion (arrows). H&E stain, ×400.
and most prominently, the hindquarters. Five dogs in the 
treated group showed proprioceptive abnormalities in-
volving the hindquarters on postural reaction test (wheel- 
barrowing, hopping, extensor postural thrust, placing, ton-
ic neck reaction, and proprioceptive positioning), starting 
on the third day of pyridoxine injection. On the fourth day 
of pyridoxine injection, five affected dogs held their hin-
dlimbs stiffly when standing. These signs remained until 
the end of the pyridoxine administration period. One dog in 
the treated group showed proprioceptive abnormalities in-
volving the hindquarters on postural reaction test, starting 
on the third day of pyridoxine injection. This dog was se-
verely affected. Hindquarter movements were stiff, spas-
tic, and dysmetric, and the dog adopted a broad-based 
stance when standing. The lack of coordination in this dog 
became so severe that it occasionally fell, especially when 
attempting to walk or turn. Except for weight loss and the 
neurological problems, there were no changes in body con-
ditions among the test animals. 
  The results of evaluation of the DEMP (M wave) and 
REMP (H-reflex) in clinically normal dogs are as follows. 
The mean M wave amplitude (5.4 ± 2.3 mV) was much 
higher than the mean H-reflex amplitude (0.5 ± 0.3 mV). 
The mean M wave latency (2.8 ± 0.3 ms) showed that the 
M wave is an early response, whereas the mean H-reflex la-
tency (16.2 ± 2.5 ms) showed that the H-reflex is a late 
response.
  Six dogs in the treated group and two dogs in the control 
group underwent electrophysiological recordings, through 
which the M wave and H-reflex were measured. In the ex-
perimental group, the amplitude of the M wave was 4.89 ± 
0.62 mV before treatment. After treatment, the amplitude 
of the M wave was 5.04 ± 0.51 mV. M wave amplitude 
showed no remarkable change after pyridoxine treatment, 
a finding confirmed in our statistical analysis (p ＜ 0.05). 
However, there was a remarkable change in the H-reflex 
after treatment in the experimental group (Fig. 1). Before 
pyridoxine treatment, the amplitude of the H-reflex was 
0.54 ± 0.06 mV. After pyridoxine treatment, there was no 
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consistently detectable H-reflex. 
  Lesions were observed in the dorsal funiculus of the lum-
bar spinal cord in experimental animals (L4). The number 
of axons was reduced, and the myelin was irregular and 
fragmented, with accompanying vacuolation (Fig. 2B). 
However, the lateral funiculi, ventral funiculus, and gray 
matter of L4 were histopathologically normal. Vacuolated 
myelin was observed in the dorsal root ganglia of L4 (Fig. 
2D). Axonal swelling and vacuolation were seen in the sci-
atic and tibial nerves (Figs. 3B and D). 
Discussion 
  Peripheral neuropathies are characterized by motor, sen-
sory, and sympathetic deficits. Sensory neuropathies are 
frequently associated with diabetes or anticancer therapies 
[2]. Vitamin deficiency, hypothyroidism, uremia, and cha-
racteristically inherited metabolic disorders are also re-
sponsible for sensory neuropathies [1]. Therefore, it is very 
important to develop animal models of sensory neuro-
pathies, in order to conduct preclinical studies of putative 
neuroprotective and neuroregenerative compounds. 
  Problematic in the development of experimentally in-
duced sensory neuropathy models are the side effects of the 
inducing treatment, such as nephrotoxicity for cisplatin, 
cardiotoxicity for taxol, and simultaneous injury of motor 
and sensory fibers for acrylamide [7]. Toxicity studies us-
ing those drugs have often successfully induced sensory 
neuropathy [1]. However, the animal model of pyridox-
ine-induced peripheral neuropathy established in this 
study was found to be selective for sensory fibers and to be 
safe for other organs [5,6]. 
  In previous experiments, reduction in body weight was 
found to be proportionate to reduction in food consumption 
[5]. In this experiment, we did not measure the amount of 
food consumption. Therefore, we found no direct correla-
tion in the reduction of food consumption and reduction in 
body weight.
  Neurologic examination is an earlier indicator of neuro-
toxicity than electrodiagnostic procedures. Therefore, neu-
rologic examinations were performed every day in this 
study, and EMG recordings were performed before and af-
ter treatments. 
  We chose to use a bipolar needle electrode for EMG re-
cordings, in contrast with electrodes used in other experi-
ments. The bipolar needle electrode is best for detecting 
correct waves without interfering error waves. However, it 
is difficult to use in humans because of the pain it causes. 
We were able to use the bipolar needle electrode in animals 
because they were anesthetized before the procedure.
  The maximal M wave amplitudes were obtained with su-
pramaximal stimulus, and the maximal H-reflex ampli-
tudes were obtained with submaximal stimulus. However, 
the H-reflex was not completely cancelled out by stimuli 
supramaximal to the direct response. In humans, the H-re-
flex is completely cancelled out when stimulation becomes 
supramaximal. This may be due to the fact that the high 
spindle density in the interosseous muscles in quadrupeds 
induces a stronger reflex [12].
  In previous rat studies, the H-reflex was measured to 
demonstrate pyridoxine-induced sensory neuropathy. In 
dogs, there have been no studies of the H-reflex in pyridox-
ine-induced sensory neuropathy. However, our study did 
utilize measurements of the H-reflex. 
  The EMG recording data obtained during peripheral 
nerve stimulation in the experimental group were con-
sistent with selective toxicity to sensory nerves. 
  An earlier study of pyridoxine toxicity in dogs and rats 
demonstrated lesions with a distribution similar to that 
seen in the experimental dogs in this study [6,8]. 
  In conclusion, we confirmed that dog models of pyridox-
ine-induced sensory neuropathy can indeed be con-
structed. Our method offers a short-term model of sensory 
neuropathy as an alternative to the already existing long- 
term model. This was the first trial in which H-reflexes 
were measured in dogs with pyridoxine-induced neuro-
pathies. Our method is advantageous in that it did not cause 
systemic toxicity. Further study is needed to confirm pyr-
idoxine-induced toxicity using electron microscopic ob-
servation.
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